Nurses can significantly reduce the risk of recurrent complications in heart patients
(10/30/2010)
( 登録している医学サイトからメールで届けられた英文レポートの要約を和訳しました。)
A six-month outpatient prevention programme conducted by nurses has resulted
in significant and sustained improvements in the control of cardiovascular
risk factors, including high cholesterol or high blood pressure, in patients
hospitalised for a heart attack or impending heart attack.
試訳:半年にわたる外来患者のための予防プログラムを実施した結果、心臓まひ及び切迫心臓まひでなど入院している患者について、高コレステロールや高血圧などの心臓血管リスク因子を封じ込めるのに、有意義かつ持続的な改善を示した。
The programme, applied in addition to standard medical care, led to the
improved adherence to current guidelines on prevention, including lifestyle
and compliance with drug treatment. The nurses were able to increase the
proportion of patients with good control of risk factors by 40% (defined
as at least seven out of nine risk factors on target) and to reduce the
calculated risk of dying in the next 10 years by about 17%.
試訳:通常の医療ケアに加え、この予防プログラムは、生活習慣改善及び薬物療法のコンプライアンスなど、現行の指針に一層沿うものとなった。看護師は、危険因子を40%抑制できた患者の割合を40%増やすことができ、今後10年間で予測死亡リスクを約17%減らすことができた。
世界中の女性の健康に貢献したい(愛媛新聞の記事より)
10/29/2010
(英訳:地元愛媛新聞の「この人」欄に掲載された医学関係の記を英訳します。)
『世界的に増えている子宮や卵巣のがん治療のかじ取り役になった。「婦人科がん治療は日本を含めて世界中でまだ標準化されていない。リードしてきた感がある欧米でもさまざま。がん患者の多いアジアやアフリカ、南米、東欧では、人々が治療レベルアップを熱望している」とみる。
対策として、婦人科がんの標準的な診察、手術、その他の治療に必要なすべてを収録した教育DVDを世界中に配りたい。そして、各国の若い医師が互いに交流するネットワークを作り、情報を共有して、がん治療を向上させ、世界中の女性の健康に貢献したい。」
子宮頸がん予防ワクチンが日本でも発売されたが、普及は遅れている。「子宮頸がんは10代後半に打てばかなり防げる。公費助成は世界中で必要」と訴える。」解剖学に忠実な手術で出血が少ない手法を確立、子宮頸がん患者の術後の排尿障害を予防できるようにした。』
Dr. Shingo Fujii is one of the leading staff at the helm of treatment of
uterus and ovarian cancers, which have increased in number worldwide. "Cancer
treatment in gynecology hasn't been standardized yet in the world as well
as in Japan." There are different standards used in Europe and the
United States, which are thought to be much advanced in this field. Craving
for the improvent in the treatment are the people in Asia, Africa, South
America and Eastern Europe, where there are a large number of cancer patients.
I would like to deliver instructive DVDs which contain necessary information
for standardized diagnosis, operation and other treatment. I also hope
to make the international network for young doctors to communicate each
other, share information and improve cancer treatment through which I want
to contribute to the health of women of the world.
Vaccine for uterin cervix cancer has been now on sale but not disseminated
yet. Uterin cervix cancer is a preventable malady if women receive vaccine
in their teens. Public subsidy is indispensable for the prevention. Dr.
Fujii,has established the anatomy-based operation method, which claims
less bleeding and has prevented dysfunctional voiding after the operation.
Why is it the barbers, not we, the physicians? (10/26/2010)
A very long time ago, barbers performed surgical procedures. Now, once
again, barbers may have a role to play in the health care of their community.
In the BARBER-1 trial, published in the Archives of Internal Medicine,
Ronald Victor and colleagues compared two hypertension monitoring and referral
programs based in 17 black-owned barbershops in Texas. Following a 10-week
period of baseline blood pressure screening, 8 shops provided standard
blood pressure pamphlets to their customers and 9 shops provided blood
pressure checks and promoted physician follow-up to their customers. After
10 months, the improvement in hypertension control was significantly higher
in the group of customers with actively involved barbers, with an absolute
difference between the groups of 8.8%.
In an accompanying commentary, Clyde Yancy considers the trial from a personal perspective “as a black man with [hypertension] who has frequented the same community barber for 17 years.” He notes that hypertension “is both an onerous risk and a scourge for the African American community” and that the BARBER-1 study suggests
“a transformative approach that might actually work.” But, he asks, “why
must we resort to a community-driven approach that abdicates the responsibility
to detect disease and institute preemptive care to well-intentioned, appropriately
trained, but nonetheless clinically naive health care providers?” He wonders
“why it is they, the barbers, and not we, the physicians, who are providing
the care.” (From CardioBrief)
注:onerous=やっかいな、scourge=災難
大意:かつては、散髪屋さんが外科的施術を行っていた事は周知のとおりだが、彼らが今再びコミュニティーにおける健康増進の役割を担うかもしれない。といっても、昔のように医療行為をするわけではなく、「店で、高血圧予防のパンフレットを配布したり、基準血圧スクリーニングができたり、医師による経過観察を勧める」ということのようだ。遺伝子学的に高血圧の傾向にある「アフリカン・アメリカン」が、散髪屋に地域の憩いの場としてのやすらぎを求めているから、自らの健康について素直に考える時間を持てるのかもしれない。
経済効率や時間効率ばかりを要求される現代社会において、散髪屋は、人々が集い、安らぐことのできるコミュニティーサロンの役割を果たしているということなのだろうか。
タイトルになっている"Why is it barbers, not we, physicians?"からは、「健康に関して、専門家の医師ではなく、門外漢である町の散髪屋が主導権を持っているのか」という医師側のやっかみも感じられて面白い。
New factor involved in depression(10/25/2010)
An enzyme known as MKP-1 is linked to depression and could potentially
be a new target for therapy of the disorder reports an article online this
week in Nature Medicine.
The prevalence and economic burden associated with depression make it
one of the most debilitating neurobiological illnesses. Despite this, the
cellular and molecular mechanisms underlying the pathophysiology of depression
are not entirely known. Ronald Duman and his colleagues applied genomic
techniques to human brain tissue from people with depression and found
increased expression of MKP-1. MKP-1 is a member of a family of enzyme
that remove phosphate groups from proteins and serves as a key negative
regulator of the mitogen-activated protein kinase (MAPK) cascade — a major
signaling pathway involved in neuronal function.
The authors tested the role of MKP-1 in rats and mice and found that increased
MKP-1 expression caused depressive behaviours. Conversely, treatment with
antidepressant normalized MKP-1 expression and behaviour, and mice lacking
MKP-1 were resilient to stress-induced depressive pathology. This therefore underscores the potential relevance of this molecule to
the pathophysiology of depression. (これらの知見は、このMKP-1がうつ病の病態生理に関わっている可能性があることを明確に示している。)
prevalence=患者数
debilitating=社会に深刻な影響を与える
underlyingt=原因となる
pathophysiology=病態生理学
increased expression=発現が亢進している
negative regulator=負の調節因子
雑誌Natureのhighlightを使って、翻訳練習をしているが、医学・科学用語は独特の表現が多く、私のような文系人間が適切な日本語に訳すのは容易なことではない。できるだけ多くの英文に触れ、そういった言い回しに慣れるしかないと思って、こつこつやっている。
Kiss of life or Keep it Simple, Stupid?
(10/16/2010) (英文記事はcardiobriefから引用)
There’s new evidence supporting the movement away from traditional bystander CPR in favor of chest-compression-only CPR. In the first meta-analysis, the investigators combined data from 3 randomized trials comparing compression-only CPR to standard CPR as directed by dispatcher instructions. The rate of survival to hospital discharge was 14% in the standard CPR group compared to 12% in the compression-only group (risk ratio 1.22, p=0.40).
However, in the second meta-analysis, the authors analyzed results from 7 observational cohort studies and found no difference between the two CPR techniques, with an 8% survival in each group. The authors noted that the second meta-analysis did not investigate dispatcher-assisted CPR. They concluded that their findings “support the idea that emergency medical services dispatch should instruct bystanders to focus on chest-compression-only CPR in adults with out-of- hospital cardiac arrest.“
大意:従来、心肺停止の患者(cardio-respiratory arrest)には、心臓マッサージ(chest-compression)と口移し式人工呼吸(kiss of life)の併用を施していたが、心臓マッサージだけを施した場合との違いが見られなかったという結果が報告されている。何の疑いもなく受け継がれてきた蘇生法だけに、「何をいまさら…」との感が否めないが、似たようなことが案外身の回りに多くあるかもしれない。
Trick or Treat? FDA staff highly critical of Aranesp trial (10/15/2010)
(英文記事はcardiobriefから)
大意:Arenespという赤血球産出刺激因子が心血管疾病や腎臓病に有効かどうかの判断をFDAが下たという記事。 検査では、その有効性が認められなかったのみならず、脳卒中や悪性腫瘍の病歴のある患者に死亡するリスクが高まったとした。 (increased the risk of stroke and increased the risk of death for those with a prior history of malignancy)
結果、標識(薬事法で、薬品を入れた容器に、その内容を正確に記載したもの)の記載変更を求めた。
Halloween arrives early on Monday for Aranesp (darbepoetin alfa), the
embattled erythropoeisis-stimulating agent (ESA), as the FDA Cardiovascular
and Renal Advisory Committee meeting considers the results of the Trial
to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). The briefing
documents, some of which have now been posted on the FDA website, suggest
the FDA will likely revise the label for Aranesp, and perhaps other ESAs
as well, and perhaps require a strict Risk Evaluation and Mitigation Strategies
(REMS).
From the executive summary of the FDA briefing document:
The TREAT trial results have been published, and the Agency agrees with
the general conclusions that the trial failed to demonstrate the anticipated
benefits of DA therapy on mortality, specific cardiovascular events (CV)
(non-fatal myocardial infarction, congestive heart failure, stroke, or
hospitalization for myocardial ischemia), and end- stage renal disease
in the CRF population not on dialysis. In addition to failing to demonstrate
benefit on either of the primary clinical endpoints, the trial provides
evidence that DA usage, as prescribed in the DA treatment arm, increased
the risk of stroke and increased the risk of death for those with a prior
history of malignancy.
Resource Use (10/13/2010)
この記事の中で使われているresource useが何を意味するのかよく分からなかったが、どうやら「患者が受ける治療サービス」のようだ。
Heart Failure and Resource Use at the End of the
Road Posted on October 12, 2010 by Larry Husten Two studies of heart
failure populations — one conducted in the U.S. and one in Canada — shed light
on patterns of resource
use in the last 6 months of life. Both studies
appear in the Archives of Internal Medicine.
Kathleen Unroe and
colleagues retrospectively analyzed resource use in a cohort of nearly
230,000 U.S. Medicare beneficiaries with heart failure who died between January
1, 2000 and December 31, 2007. Although patient use of hospice services
increased over the course of the study, overall use of resources and costs
also increased. Padma Kaul and colleagues analyzed resource usage in
some 33,000 elderly patients with heart failure who died between January 1, 2000
and December 31, 2006 in Alberta, Canada. Although costs for the patients
continued to increase during the study, the number of hospitalizations and
in-hospital deaths decreased and the use of outpatients services
increased
大意:病院内で死ぬ患者は、死亡前6か月間に膨大な治療費を支払っており、保健医療制度を圧迫している。ホスピスのサービスを受けるのも一つの選択肢だが、そのことによって他の医療サービス利用が減っているかといえば、そうではなくそれに伴う費用も増加している。カナダで2000年から2006年の間に心不全で死亡した33,000人の高齢者患者を対象とした調査では、治療費は増加し続けたが、入院数や院内死亡数は減少し、外来サービスの利用は増えた。
Obesity:Good news and Bad news
(10/13/2010)CardioBriefからの引用。
Good
news:Lifestyle interventions can result in significant weight loss. The bad
news: The results are fairly modest, and it is difficult to obtain reimbursement
for lifestyle interventions.
One study
compared usual care with a program that included free prepared meals and
counseling in 442 overweight or obese women. After 2 years, weight loss in
subjects who received prepared meals and either center-based or telephone-based
counseling was significantly greater than weight loss in subjects who received
usual care (7.4 kg and 6.2 kg vs. 2 kg). But the results probably represent
a best-case scenario and it is time to directly compare the outcomes achieved in
a variety of different commercial weight loss programs and to examine whether
providing these programs free of charge to participants would be a
cost-effective approach.
大意:良いお知らせ:通常のダイエット法で減量を試みた被験者グループと、手作り料理を食べた被験者やカウンセリングを受けた被験者のグループとの間には、著しい有意差が見られた。前者2㎏、後者7.4kg・6.2kg
A second study randomized 130 severely obese adults
(mostly women) to diet and exercise for 12 months, or to a 6-month period of
diet alone followed by 6 months of diet and exercise. At 6 months, people in the
combination diet-exercise group lost more weight than the diet-only group, but
at 12 months, weight loss was similar in the two groups. Reimbursement for
nonsurgical treatment of obesity is rare. Physicians should not be
discouraged from implementing nonsurgical medical care approaches in this
population, but payers need to rethink their policies.
大意:悪いお知らせ:ダイエット(食餌療法)と運動の組み合わせで一年間減量に取り組んだグループと最初の半年はダイエットだけで、後半の半年はダイエットと運動を組み合わせたグループとの間には、有意差は見られなかった。外科的手術を施さなければ、いずれの方法も減量効果に違いはないようだ。食餌療法や運動療法で減量を考えている人は、再考が必要だ。
"Why I won't blog about heart failure"
(10/11/2010)英文記事は、CardioBriefからの引用。
Shortly
before that time, by clicking on the titles of the two posts which I found
listed on the right side of the page under “recent posts”, I could see the first
third of the blog post and sidebar. Surprised to see a number of highlighted
words in the text of both the story and sidebar, I hovered over them and was
shocked to see what jumped out. First was the picture of a man’s face and the
message with it told me to support him for senator. Next out came an ad for baby
lotion for diaper rash. And then springing from a word in my story on heart
failure was a direct link to a website that sells genetic tests. Whoa! I’m
sending my readers to a company that sells genetic tests? A journalist could
write a story warning consumers to beware of genetic tests because of their
limitations and shortcomings. These links from my story to commercial products
were unacceptable to me. I couldn’t have ads jumping out of the words of my blog
post. I consider that USN&WR, a well-known weekly news magazine,
has crossed the line that is supposed to separate advertising from news and
editorial content. I told the magazine this and said not to publish my blog with
ads popping out of it. This separation of advertising and editorial content is a
long-held tenet of journalism.
大意:医療作家で現在Johns Hopkins Universityで教鞭をとっているMary Knudson氏の投稿記事で、彼女がなぜU.S.
News and World Report誌(USN&WR)のサイトから自身のブログ掲載を拒否するようになったかの経緯が書かれてあった。
サイト上の彼女の記事の文章中にハイライトされた単語がいくつもあり、そこからは下院議員を支持しましょうというメッセージやオムツかぶれ用のベビーローションの広告も表れた。さらに、心不全に関する彼女の記事中の単語から遺伝子検査を売り込むサイトへ直接リンクされていた。「医療ジャーナリストなら、遺伝子検査の限界と欠陥に警鐘を鳴らす記事を書けるほどなのに。」と彼女は訴える。
I have two objections to that. One is that
USN&WR is well known for its special annual rankings of best
hospitals. I would think that the magazine would consider it a conflict of
interest to have a partnership with any of the hospitals it ranks. Wouldn’t a
partnership between USN&WR and a hospital it ranks, that results in
information routinely offered to readers by that hospital on the
USN&WR website as part of news content, be interpreted as
USN&WR favoring that hospital?
まず、優良病院のランク付けをしているUSN&WRが、特定の病院とpartnershipを結んでいるのはいかがなものかと疑問を投げかけている。 My second objection is that no partnership should overtake a blogger’s
right to control what words in her blog will link elsewhere and where they will
link. Regarding linking the words “heart failure”, it would not be fitting for
me to link to a particular medical center, particularly the Cleveland Clinic. To
explain, I was diagnosed with heart failure in 2003 and had a hard time finding
good care. Once I did and started getting better, I asked my fourth
cardiologist, Edward Kasper, to write a book with me that would alert the public
to heart failure and try to find the truth as best we could about all aspects of
heart failure. I eventually recovered and have a heart that works normally.
Along the way I learned a lot that I wanted to pass on to others and I spent
years researching and writing the book with Ed, who happens to be the clinical
chief of cardiology at another pretty good hospital, the Johns Hopkins Hospital.
USN&WR was running a picture of the cover of our book alongside my
first blog post and had embedded in my accompanying bio a link to the book's
website.
次に、自身のブログ中の「心不全」という単語から特定の病院-Cleveland Clinic-にリンクが張られているのは受け入れられないとも訴えている。彼女は、利害関係にとらわれないサイトで心臓疾病に関する情報を伝えたいとの想いから、全米ネットワークを持つ健康に関するブログ開設に向けて準備している。
Rolofylline Fails (10/8/2010) 英文記事は、CardioBriefからの引用。
Massie and colleagues randomized 2033 patients hospitalized with acute
heart failure and impaired renal function to receive intravenous roloflylline
or placebo. Earlier studies had suggested that the use of an adenosine
A1-receptor antagonist might be beneficial in this patient population. There was no difference between the two groups in the primary
endpoint, which was based on survival, heart-failure status, and changes in
renal function. At 60 days the rate of death or readmission for cardiovascular
or renal causes was similar in both groups. The authors concluded that
rolofylline “does not show promise in the treatment of acute heart failure with
renal dysfunction.”
大意:The New England Journal of Medicineによると、治験薬rolofyllineを2033人の心不全および腎機能障害の患者に投与したところ、primary endpoint(主要評価項目)において、プラセボグループとの差異は見られなかったということだ。評価項目は、生存率、心不全や腎機能の改善など。
By 60 days, death or readmission for cardiovascular or renal
causes had occurred in similar proportions of patients assigned to rolofylline
and placebo (30.7% and 31.9%, respectively; P=0.86). Adverse-event rates were
similar overall; however, only patients in the rolofylline group had seizures, a
known potential adverse effect of A1-receptor
antagonists.
投与60日後の死亡率、心循環器と腎臓由来の再入院率において、30.7%と31.9%と殆ど違いがなかった。有害事象発生率は同レベルだったものの、発作が起こったのはrolofyllineを投与したグループだった。
Insufficient Sleep
Undermines Dietary Efforts to Reduce Adiposity(10/5/2010)
英文記事は、CardioBriefからの引用。
Results: Sleep curtailment decreased the proportion of weight lost as fat by 55%
(1.4 vs. 0.6 kg with 8.5 vs. 5.5 hours of sleep opportunity, respectively;
P =
0.043) and increased the loss of fat-free body mass by 60% (1.5 vs. 2.4 kg;
P = 0.002). This was accompanied by markers of enhanced neuroendocrine
adaptation to caloric restriction, increased hunger, and a shift in relative
substrate utilization toward oxidation of less fat.
Conclusion: The
amount of human sleep contributes to the maintenance of fat-free body mass at
times of decreased energy intake. Lack of sufficient sleep may compromise the
efficacy of typical dietary interventions for weight loss and related metabolic
risk reduction.
大意:睡眠とダイエットに深い相関関係があるとした研究。
Subjects(被験者)にそれぞれ8時間半と5時間半の睡眠を与えた結果、脂肪分の減量が前者1.4kgで後者0.6kg、脂肪分を除く体重の減少はそれぞれ1.5kgと2.4kgであった。
つまり、摂取エネルギー量を減らせば、十分な睡眠時間が脂肪のない身体の維持に貢献し、睡眠時間が不十分であると、減量ダイエット効果やメタボ対策効果が弱まる。
Acromegaly (8/24/2010)
The wrestler, Choi Hong-man, is an example of acromegaly, which comes from the Greek words for
"extremities"(acro) and "great"(megaly), because one of the most common symptoms
of this condition is abnormal growth of the hands and feet. He had to refrain
himself from fighting tournaments due to the pituitary gland tumor, which may
result in an altered facial appearance, enlargement of the hands and feet,
sleep apnea, and carpal tunnel syndrome. More serious problems may include
accelerated cardiovascular disease, hypertension, diabetes mellitus and
possibly an increased risk of colon cancer. If the tumor develops before
bone growth is completed in adolescence, the result will be gigantism.
Patients with this disease had to pay for expensive medical expense for the
treatment; however, it has been designated as incurable disease, which greatly
relieve the financial burden.
Rimonabant
(8/18/2010) Rimonabant is a drug for obesites, reducing appetite,
and ultimately food consumption. The European Medicines Agency recommended
doctors no longer prescribe rimonabant from October 2008, referring to no
evidence for rimonabant’s prevention of adverse cardiovascular outcomes while
rimonabant causes the effect of inducing serious neuropsychiatric
side-effect.
Four patients in the rimonabant group (0.04%) and one in the
placebo group (0.01%) committed suicide. 364 (3·9%) patients assigned to
rimonabant and375 (4·0%) assigned to placebo. With rimonabant, gastrointestinal
(33% vs 22%), neuropsychiatric (32% vs 21%), and serious psychiatric
side-effects (2·5% vs 1·3%) were significantly increased compared with placebo. In consequence, people with
obesity should control their caloric intake and increase physical activity
instead of relying on such drugs as rimonabant with potential side-effects.
Sounds simple but easier said than done.
Breast Cancer
(7/29)
For women, the major killer is breast cancer. There have been no dramatic
development on the life expectacy of patients diagnosed with this disease.
In terms of not just the duration of survival, but the quality of the survival,
more women are opting for mastectomy rather than lumpectomy though mastectomy
seems to cause more serious side-effects and physical distress as well
as psychological distress. Actually, however, local excision remains the
high risk of recurrence. About 20 percent of women treated by lumpectomy
probably end up having a mastectomy, which for some women is quite unacceptable.
That's why when given a choice, if patients are truly informed of all the
various risks involved with the different procedures, most of them will
still prefer to opt for mastectomy. Avoiding radiotherapy is another reason
for the option. For
mammographic screening women from the age of 50 to 65 are the optimal age group,
because that group seemed to achieve most benefit in terms of early detection of
the disease. If that group is screened once every three years, we could reduce
the mortality from breast cancer by 25 percent.
Developmental
Disorders (7/27)
ADHD, which stands for attention deficit hyperactivity disorder,
is regarded as a disruptive behavior disorder. The school children with this
disease break the rules in a classroom. It is said that excessive number of
children are diagnosed with ADHD for doctors tend to apply criteria
inaccurately. Even doctors have difficulty making the diagnosis of ADHD,
and then how could teachers properly treat the children with this disease? The
fact that ADHD tends to run in family also makes the problem more sensitive and
complicated. If early intensive educational intervention is the only
effective approach for this disease, the MEXT should show clear guidlines for
behavioral method and therapy.
Is it safe? (7/25)
This is not necessarily
a matter of medicine, but here "Is it safe?" is kept using in the
conversation between a dentist and a patient. Interestingly, it is not a patient
but a dentist who repeats this phrase. Oliveir played a Nazi dentist and Hoffman
a patient in the film, Marathon Man.
Olivier: Is it
safe? Hoffman: You’re talking to
me? Olivier: Is it safe? Hoffman: Is what safe? Olivier: Is it safe? Hoffman: I don’t know what you mean.
I can’t tell you something’s safe or not, unless I know specifically
what you’re talking about. Olivier: Is it safe? Hoffman: Tell
me what the “it” refers to. Olivier: Is it
safe? Hoffman: Yes, it’s safe, it’s very safe,
it’s so
safe you wouldn’t believe it. Olivier: Is it safe? Hoffman: No.
It’s not safe, it’s… very
dangerous, be careful. This conversation is implausible, but it implies something
essential in our life. The same question was kept pouring while the answers
varied from Yes to No. How could it happen? It is because the patient has no
idea of what is going on. We need to collect information and analize the fact,
which is the only way to reach the truth.
Tumor (6/24) A
medulloblastoma is a tumor that arise from poorly developmental cells in the
inner part of the body. … certain developmental malformations or
inflammatory masses may occasionally be called tumors. In the above two
sentences, the term "developmental" is used; however, doctors claim that
"developmental" be "differentiated." Poorly differentiated refers to how the
cancer cells look under a microscope, which means the cells do not look much
like normal breast cells. As normal cells develop, they differentiate, which
means they change and become specialized depending on where in the body they
are. For example, breast cells look differnt from liver cells. Therefore, it is
important for cells to change and be differential. cf. differentiated =
分化された
Alzheimer (6/19) Alzheimer’s Disease is the most common
type of dementia. Dementia, which affects the brain and memory and makes you
gradually lose the ability to think normally, occurs as a result of changes in
the brain. It can become severe enough to affect daily
activities. Alzheimer's Disease is not a normal part of aging. No one knows
what causes Alzheimer’s Disease, but much research is being done. You may be
more at risk if you had a family member with the disease. The signs start
slowly and can vary or worsen over time. A person cannot control the
signs.Treatment can help, but it does not cure the disease. Signs may
include: •Memory loss, especially about recent events •Confusion about
time and place •Poor judgment •Trouble learning new
information •Changes in being able to do such things as drive, handle money,
take medicine, cook, dress and bathe Looking at signs of Alzheimer's
disease, there are some that I've been suffering from for these several years.
They may come from either a mere aging or Alzheimer's disease. I find quite hard
especially in remembering people's names; movie stars, comedians, singers,
athletes, etc. Withstanding the fear of the disease, I'm learning things new,
which entails trials and errors and can be often stressful. I feel, however, it
is worthy of trying and endows me with mental satisfaction any other thing could
not offer.
Lifestyle disease (5/24) Lifestyle disease is
something far away from me and so do I believe. I am slim , non-smoker, take
much exercise and don't drink at all. Is there anything else necessary to ward
off lifestyle disease? If you were a doctor, you might pontificate or point out
with an air of importance; "Don't you like taking hard exercise, which makes you
panting?" "Don't you like sweets?"
Yes, you are right. I might have taken
too much exercise. I like running fast more than walking or jogging. I've
allowed myself to eat sweets after some exercise for it's a good excuse. I don't
like to see my body deteriorating and try to do any exercise whatsoever
regularly to keep myself in good shape: push-ups, sit-ups, calf raise and so
forth. Consequently, I've tried to keep myself healthy in vain. The idea of
lifestyle disease may change my whole lifestyle; eat less and exercise
less.
注:英文のみのarticleは、私が書いたもの。大意を載せているarticleは、主にCardioBriefから引用したものである。
|
|